1
2
3

Information List

Wuxi Beta Obtain High-tech Enterprise Certificate

2018-10-25

On December 7, 2017, Wuxi Beta Pharmaceutical Technology Co., Ltd. obtained the certificate of high-tech enterprise in Jiangsu Province. So far, Wuxi Beta has obtained a total of 16 patents, published 9 academic papers in well-known journals and academic conferences at home and abroad, overcome a number of technical difficulties, created 5 "gold standard" products and technologies, and developed more than 400 kinds of isotope labeling products. These technological innovations have brought broad development prospects to Wuxi Beta.

Wuxi Beta establishes partnership with Swiss RC TRITECH

2018-10-25

On May 15, 2017, Wuxi Beta Pharmaceutical Technology Co., Ltd. established a cooperation with Swiss RCTRITECH Company to provide technical services for tritium labeling for new drug development in China. In our country, the tritium label of drugs has not been provided by professional companies. This cooperation will provide great convenience for our customers who need tritium label and open up a shortcut for the development of tritium label technology in our country.

Wuxi Beta Obtain C- 14 and H-3 Radiation Safety License

2018-10-25

On May 15, 2017, Wuxi Beta Pharmaceutical Technology Co., Ltd. completed the construction of a non-sealed radioactive material workplace and obtained a C- 14 and H-3 radiation safety license. Wuxi Beta has been engaged in the simulation research and development of C14 labeled precursor compounds since 2009 and the cooperative research and development of C14 source materials since 2010. By October 2016, these tasks have been basically completed and a solid foundation for development has been established. At this time, the acquisition of radiation safety license marks the formal opening of China's professional C14 marking service.

Technical Summary Exchange Meeting of China Nuclear Power Research and Design Institute Held in Chengdu

2018-10-25

On October 29, 2016, China Nuclear Power Research and Design Institute held a technical summary exchange meeting in Chengdu, announcing the success of the localization of C14 source materials. In September 2010, under the coordination and guidance of Academician Zhou Yongmao and Academician Sun Yufa, Wuxi Beta Pharmaceutical Technology Co., Ltd. established a cooperative relationship with China Nuclear Power Research and Design Institute. After 6 years of unremitting efforts, it finally overcame the difficulties. The localization of C14 source materials was realized, and a solution was established for the international shortage of C14.

Wuxi Beta and Shanghai Medissi Biotechnology Co., Ltd. to establish a cooperative relationship

2018-10-25

On June 24, 2016, Wuxi Beta Pharmaceutical Technology Co., Ltd. and Shanghai Medisi Biotechnology Co., Ltd. signed a framework agreement to complement each other's advantages and do their best to cooperate in the development of C14 labeling of Chinese medicine and animal drug generation research. Actively promote the development of my country's new drug development industry.

< 12345 >